Skip to main content
Top
Published in: Diabetologia 4/2015

01-04-2015 | Article

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes

Authors: Siri Fredheim, Marie-Louise M. Andersen, Sven Pörksen, Lotte B. Nielsen, Christian Pipper, Lars Hansen, Jens J. Holst, Jane Thomsen, Jesper Johannesen, Henrik B. Mortensen, Jannet Svensson

Published in: Diabetologia | Issue 4/2015

Login to get access

Abstract

Aims/hypothesis

The influence of glucagon on glycaemic control in type 1 diabetes is debated. We investigated the relationship between postprandial glucagon levels and HbA1c during a period up to 60 months after diagnosis of childhood type 1 diabetes.

Methods

The Danish remission phase cohort comprised 129 children (66 boys) with type 1 diabetes whose mean (SD) age at onset was 10.0 (3.9) years. Liquid mixed-meal tests were performed prospectively at 1, 3, 6 and 12 months and a subset of 40 patients completed follow-up at 60 months. Postprandial (90 min) plasma levels of glucagon, glucose (PG), C-peptide, total glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and HbA1c were analysed. Multivariate regression (repeated measurements with all five visits included) was applied and results expressed as relative change (95% CI).

Results

Postprandial glucagon levels increased 160% from 1 to 60 months after diagnosis (p < 0.0001). A doubling in postprandial PG corresponded to a 21% increase in postprandial glucagon levels (p = 0.0079), whereas a doubling in total GLP-1 levels corresponded to a 33% increase in glucagon levels (p < 0.0001). Postprandial glucagon associated negatively with postprandial C-peptide (p = 0.017). A doubling in postprandial glucagon corresponded to a 3% relative increase in HbA1c levels (p = 0.0045).

Conclusions/interpretation

Postprandial glucagon levels were associated with deterioration of glycaemic control and declining beta cell function in the first 5 years after diagnosis of type 1 diabetes. The positive association of glucagon with total GLP-1 and PG suggests that physiological regulation of alpha cell secretion in type 1 diabetes is seriously disturbed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walker JN, Ramracheya R, Zhang Q, Johnson PRV, Braun M, Rorsman P (2011) Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(1):95–105CrossRefPubMed Walker JN, Ramracheya R, Zhang Q, Johnson PRV, Braun M, Rorsman P (2011) Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(1):95–105CrossRefPubMed
2.
go back to reference Samols E, Tyler JM, Mialhe P (1969) Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet 1:174–176CrossRefPubMed Samols E, Tyler JM, Mialhe P (1969) Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet 1:174–176CrossRefPubMed
3.
go back to reference Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296–2299CrossRefPubMedCentralPubMed Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296–2299CrossRefPubMedCentralPubMed
4.
go back to reference Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116CrossRefPubMed Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116CrossRefPubMed
5.
go back to reference Braun M, Ramracheya R, Amisten S et al (2009) Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia 52:1566–1578CrossRefPubMed Braun M, Ramracheya R, Amisten S et al (2009) Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia 52:1566–1578CrossRefPubMed
6.
go back to reference Taborsky GJ Jr, Ahrén B, Havel PJ (1998) Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 47:995–1005CrossRefPubMed Taborsky GJ Jr, Ahrén B, Havel PJ (1998) Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 47:995–1005CrossRefPubMed
7.
go back to reference Marty N, Dallaporta M, Thorens B (2007) Brain glucose sensing, counterregulation, and energy homeostasis. Physiology Bethesda 22:241–251CrossRefPubMed Marty N, Dallaporta M, Thorens B (2007) Brain glucose sensing, counterregulation, and energy homeostasis. Physiology Bethesda 22:241–251CrossRefPubMed
8.
go back to reference Cabrera O, Jacques-Silva MC, Speier S et al (2008) Glutamate is a positive autocrine signal for glucagon release. Cell Metab 7:545–554CrossRefPubMed Cabrera O, Jacques-Silva MC, Speier S et al (2008) Glutamate is a positive autocrine signal for glucagon release. Cell Metab 7:545–554CrossRefPubMed
9.
go back to reference Molina J, Rodriguez-Diaz R, Fachado A, Jacques-Silva MC, Berggren P-O, Caicedo A (2014) Control of insulin secretion by cholinergic signaling in the human pancreatic islet. Diabetes 63:2714–2726CrossRefPubMed Molina J, Rodriguez-Diaz R, Fachado A, Jacques-Silva MC, Berggren P-O, Caicedo A (2014) Control of insulin secretion by cholinergic signaling in the human pancreatic islet. Diabetes 63:2714–2726CrossRefPubMed
10.
go back to reference Hope KM, Tran POT, Zhou H, Oseid E, Leroy E, Robertson RP (2004) Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the “switch-off” hypothesis. Diabetes 53:1488–1495CrossRefPubMed Hope KM, Tran POT, Zhou H, Oseid E, Leroy E, Robertson RP (2004) Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the “switch-off” hypothesis. Diabetes 53:1488–1495CrossRefPubMed
11.
go back to reference Banarer S, McGregor VP, Cryer PE (2002) Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958–965CrossRefPubMed Banarer S, McGregor VP, Cryer PE (2002) Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958–965CrossRefPubMed
12.
go back to reference Brown RJ, Sinaii N, Rother KI (2008) Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31:1403–1404CrossRefPubMedCentralPubMed Brown RJ, Sinaii N, Rother KI (2008) Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31:1403–1404CrossRefPubMedCentralPubMed
13.
go back to reference Arbelaez AM, Xing D, Cryer PE et al (2014) Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes 15:127–134CrossRefPubMedCentralPubMed Arbelaez AM, Xing D, Cryer PE et al (2014) Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes 15:127–134CrossRefPubMedCentralPubMed
14.
go back to reference Sherr J, Xing D, Ruedy KJ et al (2013) Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes. Diabetes Care 36:1470–1476CrossRefPubMedCentralPubMed Sherr J, Xing D, Ruedy KJ et al (2013) Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes. Diabetes Care 36:1470–1476CrossRefPubMedCentralPubMed
15.
go back to reference Pörksen S, Nielsen LB, Kaas A et al (2007) Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 92:2910–2916CrossRefPubMed Pörksen S, Nielsen LB, Kaas A et al (2007) Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 92:2910–2916CrossRefPubMed
16.
go back to reference Sherr J, Tsalikian E, Fox L et al (2014) Evolution of abnormal plasma glucagon responses to mixed meal feedings in youth with type 1 diabetes during the first two years after diagnosis. Diabetes Care 37:1741–1744CrossRefPubMed Sherr J, Tsalikian E, Fox L et al (2014) Evolution of abnormal plasma glucagon responses to mixed meal feedings in youth with type 1 diabetes during the first two years after diagnosis. Diabetes Care 37:1741–1744CrossRefPubMed
17.
18.
go back to reference Andersen MLM, Nielsen LB, Svensson J et al (2014) Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. Pediatr Diabetes 15:345–354CrossRef Andersen MLM, Nielsen LB, Svensson J et al (2014) Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. Pediatr Diabetes 15:345–354CrossRef
19.
go back to reference Max Andersen MLC, Hougaard P, Pörksen S et al (2014) Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes. Pediatr Diabetes 15:469–476CrossRefPubMed Max Andersen MLC, Hougaard P, Pörksen S et al (2014) Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes. Pediatr Diabetes 15:469–476CrossRefPubMed
20.
go back to reference Bak MJ, Albrechtsen NW, Pedersen J et al (2014) Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 170:529–538CrossRefPubMed Bak MJ, Albrechtsen NW, Pedersen J et al (2014) Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 170:529–538CrossRefPubMed
21.
go back to reference Wewer Albrechtsen NJ, Hartmann B, Veedfald S et al (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57:1919–1926CrossRefPubMed Wewer Albrechtsen NJ, Hartmann B, Veedfald S et al (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57:1919–1926CrossRefPubMed
22.
go back to reference Dunger DB, Sperling MA, Acerini CL et al (2004) ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 89:188–194CrossRefPubMedCentralPubMed Dunger DB, Sperling MA, Acerini CL et al (2004) ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 89:188–194CrossRefPubMedCentralPubMed
23.
go back to reference Dunger DB, Sperling MA, Acerini CL et al (2004) European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics 113:e133–e140CrossRefPubMed Dunger DB, Sperling MA, Acerini CL et al (2004) European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics 113:e133–e140CrossRefPubMed
24.
go back to reference Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ (2008) Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 9:165–174CrossRefPubMed Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ (2008) Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 9:165–174CrossRefPubMed
25.
go back to reference Urakami T, Nagano N, Suzuki J, Yoshida A, Takahashi S, Mugishima H (2011) Influence of plasma glucagon levels on glycemic control in children with type 1 diabetes. Pediatr 53:46–49 Urakami T, Nagano N, Suzuki J, Yoshida A, Takahashi S, Mugishima H (2011) Influence of plasma glucagon levels on glycemic control in children with type 1 diabetes. Pediatr 53:46–49
26.
go back to reference Kramer CK, Borgoño CA, van Nostrand P, Retnakaran R, Zinman B (2014) Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 37:1076–1082CrossRefPubMed Kramer CK, Borgoño CA, van Nostrand P, Retnakaran R, Zinman B (2014) Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 37:1076–1082CrossRefPubMed
27.
go back to reference Hansen L, Hartmann B, Mineo H, Holst JJ (2004) Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118:11–18CrossRefPubMed Hansen L, Hartmann B, Mineo H, Holst JJ (2004) Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118:11–18CrossRefPubMed
28.
go back to reference Gribble FM, Williams L, Simpson AK, Reimann F (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147–1154CrossRefPubMed Gribble FM, Williams L, Simpson AK, Reimann F (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147–1154CrossRefPubMed
29.
go back to reference Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687CrossRefPubMed Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687CrossRefPubMed
30.
go back to reference Kielgast U, Holst JJ, Madsbad S (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60:1599–1607CrossRefPubMedCentralPubMed Kielgast U, Holst JJ, Madsbad S (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60:1599–1607CrossRefPubMedCentralPubMed
31.
go back to reference Kielgast U, Asmar M, Madsbad S, Holst JJ (2010) Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 95:2492–2496CrossRefPubMed Kielgast U, Asmar M, Madsbad S, Holst JJ (2010) Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 95:2492–2496CrossRefPubMed
32.
go back to reference Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed
33.
go back to reference Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK (2011) Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 28:1176–1181CrossRefPubMed Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK (2011) Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 28:1176–1181CrossRefPubMed
34.
go back to reference Foley JE, Ligueros-Saylan M, He Y-L et al (2008) Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 40:727–730CrossRefPubMed Foley JE, Ligueros-Saylan M, He Y-L et al (2008) Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 40:727–730CrossRefPubMed
35.
go back to reference Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:1463–1468CrossRefPubMedCentralPubMed Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:1463–1468CrossRefPubMedCentralPubMed
36.
go back to reference Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300:E1038–E1046CrossRefPubMed Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300:E1038–E1046CrossRefPubMed
37.
go back to reference Christensen M, Calanna S, Sparre-Ulrich AH et al (2014) Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. doi:10.2337/db14-0440 Christensen M, Calanna S, Sparre-Ulrich AH et al (2014) Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. doi:10.​2337/​db14-0440
38.
go back to reference De Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263–2270CrossRefPubMed De Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263–2270CrossRefPubMed
39.
go back to reference Besser REJ, Shields BM, Casas R, Hattersley AT, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36:195–201CrossRefPubMedCentralPubMed Besser REJ, Shields BM, Casas R, Hattersley AT, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36:195–201CrossRefPubMedCentralPubMed
Metadata
Title
The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes
Authors
Siri Fredheim
Marie-Louise M. Andersen
Sven Pörksen
Lotte B. Nielsen
Christian Pipper
Lars Hansen
Jens J. Holst
Jane Thomsen
Jesper Johannesen
Henrik B. Mortensen
Jannet Svensson
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3486-3

Other articles of this Issue 4/2015

Diabetologia 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.